NasdaqGS - Delayed Quote USD

Surmodics, Inc. (SRDX)

25.39 -1.10 (-4.15%)
At close: April 22 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Gary R. Maharaj CEO, President & Director 1.33M -- 1963
Mr. Timothy J. Arens Senior VP of Finance & Information Technology and CFO 645.3k 59.73k 1967
Mr. Gordon S. Weber Senior VP of Legal, General Counsel & Secretary 602.84k -- 1963
Mr. Charles W. Olson Senior VP & President of Medical Device Coatings 618.47k -- 1964
Ms. Teryl L. W. Sides Senior VP & President of Vascular Interventions 744.38k -- 1970
Mr. John D. Manders Corporate Controller, VP of Finance & Principal Accounting Officer -- -- 1981
Mr. Joseph J. Stich Senior VP of Human Resources & President of In Vitro Diagnostics 570.92k 501.23k 1965

Surmodics, Inc.

9924 West 74th Street
Eden Prairie, MN 55344-3523
United States
952 500 7000 https://www.surmodics.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
376

Description

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Corporate Governance

Surmodics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 4. The pillar scores are Audit: 6; Board: 2; Shareholder Rights: 5; Compensation: 5.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 01, 2024
Surmodics, Inc. Earnings Call

Related Tickers

ESMC Escalon Medical Corp.
0.2470
0.00%
 
ZIMV ZimVie Inc.
15.49
+0.39%
 
KIDS OrthoPediatrics Corp.
30.20
-0.36%
 
CNMD CONMED Corporation
72.61
-0.04%
 
VREX Varex Imaging Corporation
17.06
+0.41%
 
XTNT Xtant Medical Holdings, Inc.
0.8400
+1.20%
 
SIBN SI-BONE, Inc.
15.56
+0.91%
 
CTKB Cytek Biosciences, Inc.
5.80
-2.03%
 
PEN Penumbra, Inc.
203.00
+0.14%
 
TCMD Tactile Systems Technology, Inc.
14.65
+1.74%